Revolution Medicines (RVMD) Income towards Parent Company (2019 - 2026)
Revolution Medicines' quarterly Income towards Parent Company came in at -$453.8 million in Q1 2026, down 112.64% year-on-year from $3.6 billion in Q1 2025, and down 159.21% quarter-over-quarter from $766.4 million in Q4 2025.
Revolution Medicines has reported Income towards Parent Company for 8 years, with the latest figure at -$453.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 112.64% year-over-year to -$453.8 million; the trailing twelve-month figure through Mar 2026 stood at -$240.4 million (up 65.53% YoY), and the FY2024 full-year result was -$600.0 million, down 36.31% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$453.8 million, down from $766.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was $766.4 million in Q4 2025, with the low at -$453.8 million in Q1 2026.
- Average Income towards Parent Company over 5 years is -$102.5 million, with a median of -$116.0 million recorded in 2024.
- Year-over-year, Income towards Parent Company plunged 192.58% in 2023 and soared 494.0% in 2025.
- Tracing RVMD's Income towards Parent Company over 5 years: stood at -$56.5 million in 2022, then plunged by 192.58% to -$165.4 million in 2023, then declined by 17.62% to -$194.5 million in 2024, then soared by 494.0% to $766.4 million in 2025, then slumped by 159.21% to -$453.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$453.8 million (Q1 2026), $766.4 million (Q4 2025), and -$305.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | 766.41 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.52 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -165.39 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.53 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |
| Jun 30, 2021 | -44.30 Mn |
| Mar 31, 2021 | -37.18 Mn |
| Dec 31, 2020 | -34.20 Mn |
| Sep 30, 2020 | -27.22 Mn |
| Jun 30, 2020 | -27.22 Mn |
| Mar 31, 2020 | -19.52 Mn |
| Dec 31, 2019 | -18.97 Mn |
| Sep 30, 2019 | -12.82 Mn |
| Jun 30, 2019 | -10.12 Mn |
| Mar 31, 2019 | -10.13 Mn |